Press release
Pulmonary arterial hypertension Clinical Trials 2024: EMA, PDMA, FDA Approvals, Therapies, Medication, Treatment Market, MOA, ROA, and Companies by DelveInsight
Pulmonary arterial hypertension Clinical Trials
Key Takeaways from the Pulmonary arterial hypertension Pipeline Report
• DelveInsight's Pulmonary arterial hypertension pipeline report depicts a robust space with 55+ active players working to develop 55+ pipeline therapies for Pulmonary arterial hypertension treatment.'
• The leading Pulmonary arterial hypertension Companies working in the market include Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic, and others.
• Promising Pulmonary Arterial Hypertension Pipeline Therapies include Bardoxolone methyl, L606, Ralinepag, Sotatercept, Inhaled Nitric Oxide, Autologous EPCs transfected with human eNOS, MK-5475, Alunacedase alfa, ABI-009, BAY1237592, LTP001, AV-101, CS1, GB002, rodatristat ethyl, GMA301, RT234, Apabetalone, AER-901, TPN171H, ,RBM-011, VPD-380, MGX 292, BZ371, TOP-V122, Belapectin, PT001, KER-012, SUL-150, LT-2004, LAM-001, RP5063, SI-F019, NTP42, CAM2043, CPL409116, PDNO, Zamicastat, PB1046, R-107, H01, ALT-100, and others.
• April 2024: Insmed Incorporated- An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension.
• April 2024: Bayer- Open-label, Individual Dose Titration Study to Evaluate Safety, Tolerability and Pharmacokinetics of Riociguat in Children From 6 to Less Than 18 Years of Age With Pulmonary Arterial Hypertension (PAH).
• April 2024:- Merck Sharp & Dohme LLC- A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Arterial Hypertension.
Request a sample and discover the recent advances in Pulmonary arterial hypertension Treatment Drugs @ Pulmonary arterial hypertension Pipeline Report- https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
In the Pulmonary arterial hypertension pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pulmonary arterial hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Pulmonary arterial hypertension Overview
Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening blood vessel disorder. PAH is characterized by a thickening of the pulmonary vasculature, leading to restricted blood flow and elevated blood pressure within the pulmonary vessels. The tests that are commonly performed to diagnose PAH and rule out other diseases are echocardiography, blood tests, pulmonary function tests, X-rays of the chest, lung blood flow scans, electrocardiography (ECG), and the "6-minute walk test", which measures how far an individual can walk in that time period.
Find out more about Pulmonary arterial hypertension Therapeutics Assessment @ Pulmonary arterial hypertension Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Pulmonary arterial hypertension Emerging Drugs Profile
• Sotatercept: Acceleron Pharma
Sotatercept is a first-in-class therapeutic fusion protein comprised of the extracellular domain of human activin receptor type IIA, fused to the Fc domain of human immunoglobulin G1 (IgG1). It provides balance of the growth-promoting activin growth differentiation factor pathway, and the growth-inhibiting BMP pathway by serving as a ligand trap for the TGF-β superfamily. The United States Food and Drug Administration (FDA) has granted Orphan Drug designation and Breakthrough Therapy designation to sotatercept for the treatment of PAH; the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of PAH. Sotatercept is in Phase III clinical trial for the treatment of PAH.
• LIQ861: Liquidia Technologies
LIQ861 is an investigational, inhaled dry powder formulation of treprostinil designed using the Company's novel PRINT technology and engineered with the goal of enhancing deep-lung delivery of treprostinil in PAH patients by means of a convenient, palm-sized dry powder inhaler. Liquidia resubmits New Drug Application for LIQ861 under the 505(b)(2) regulatory pathway for the treatment of pulmonary arterial hypertension (PAH).
Pulmonary Arterial Hypertension: Therapeutic Assessment
There are approx. 55+ key companies which are developing the therapies for Pulmonary Arterial Hypertension. The companies which have their Pulmonary Arterial Hypertension drug candidates in the most advanced stage, i.e. Preregistration include, Liquidia Technologies.
DelveInsight's Pulmonary arterial hypertension pipeline report covers around 55+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Pulmonary Arterial Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type
Pulmonary arterial hypertension Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Learn more about the emerging Pulmonary arterial hypertension Pipeline Therapies @ Pulmonary arterial hypertension Clinical Trials Assessment- https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Pulmonary arterial hypertension Pipeline Report
• Coverage- Global
• Pulmonary arterial hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Pulmonary arterial hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Pulmonary arterial hypertension Companies- Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic, and others.
• Pulmonary Arterial Hypertension Pipeline Therapies- Bardoxolone methyl, L606, Ralinepag, Sotatercept, Inhaled Nitric Oxide, Autologous EPCs transfected with human eNOS, MK-5475, Alunacedase alfa, ABI-009, BAY1237592, LTP001, AV-101, CS1, GB002, rodatristat ethyl, GMA301, RT234, Apabetalone, AER-901, TPN171H, ,RBM-011, VPD-380, MGX 292, BZ371, TOP-V122, Belapectin, PT001, KER-012, SUL-150, LT-2004, LAM-001, RP5063, SI-F019, NTP42, CAM2043, CPL409116, PDNO, Zamicastat, PB1046, R-107, H01, ALT-100, and others.
Dive deep into rich insights for new drugs for Pulmonary arterial hypertension Treatment, Visit @ Pulmonary arterial hypertension Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Pulmonary Arterial Hypertension: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Pulmonary Arterial Hypertension - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Sotatercept: Acceleron Pharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. GB-002: Gossamer Bio
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Apabetalone: Resverlogix
15. Drug profiles in the detailed report…..
16. Preclinical/Discovery Stage Products
17. R107: Radikal Therapeutics
18. Inactive Products
19. Pulmonary Arterial Hypertension Key Companies
20. Pulmonary Arterial Hypertension Key Products
21. Pulmonary Arterial Hypertension- Unmet Needs
22. Pulmonary Arterial Hypertension- Market Drivers and Barriers
23. Pulmonary Arterial Hypertension- Future Perspectives and Conclusion
24. Pulmonary Arterial Hypertension Analyst Views
25. Appendix
For further information on the Pulmonary arterial hypertension Pipeline therapeutics, reach out to Pulmonary arterial hypertension Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Actinic Keratosis Market: https://www.delveinsight.com/report-store/actinic-keratosis-market
• Anaphylaxis Market: https://www.delveinsight.com/report-store/anaphylaxis-market
• Anemia In Ckd Market: https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/anti-cd274-pd-l1-antibody-pipeline-insight
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Artificial Lung Devices Market: https://www.delveinsight.com/report-store/artificial-lung-devices-pipeline-insight-and-competitive-landscape
• Atopic Keratoconjunctivitis Akc Market: https://www.delveinsight.com/report-store/atopic-keratoconjunctivitis-market
• Biliary Stents Market: https://www.delveinsight.com/report-store/biliary-stents-market
• Biochips Market: https://www.delveinsight.com/report-store/biochips-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Diabetic Foot Ulcers Dfus Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Generalized Anxiety Disorder Gad Market: https://www.delveinsight.com/report-store/generalized-anxiety-disorder-gad-market
• Generalized Anxiety Disorder Market: https://www.delveinsight.com/report-store/generalized-anxiety-disorder-gad-market
• Head And Neck Cancer Market: https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-market
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Neuroblastoma Market: https://www.delveinsight.com/report-store/neuroblastoma-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Pediatric Obesity Market: https://www.delveinsight.com/report-store/pediatric-obesity-market
• Polycythemia Vera Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary arterial hypertension Clinical Trials 2024: EMA, PDMA, FDA Approvals, Therapies, Medication, Treatment Market, MOA, ROA, and Companies by DelveInsight here
News-ID: 3703242 • Views: …
More Releases from DelveInsight Business Research
Autism Spectrum Disorders Market Trends Point to Steady Growth Ahead by 2034, De …
DelveInsight's "Autism Spectrum Disorders Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Autism Spectrum Disorders, historical and forecasted epidemiology as well as the Autism Spectrum Disorders market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Autism Spectrum Disorders market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Autism Spectrum Disorders…
Pulmonary Sarcoidosis Market Dynamics Indicate Upward Trajectory Through 2032, R …
The Pulmonary Sarcoidosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pulmonary Sarcoidosis pipeline products will significantly revolutionize the Pulmonary Sarcoidosis market dynamics.
DelveInsight's "Pulmonary Sarcoidosis Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Pulmonary Sarcoidosis, historical and forecasted epidemiology as well as the Pulmonary Sarcoidosis market trends in the United…
Prader-Willi Syndrome Market to Experience Notable Growth in Forecast Span by 20 …
DelveInsight's "Prader-Willi Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Prader-Willi Syndrome, historical and forecasted epidemiology as well as the Prader-Willi Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The Prader-Willi Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Prader-Willi Syndrome pipeline…
Aspergillosis Pipeline 2025: Key Developments, Emerging Therapies, and Clinical …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Aspergillosis pipeline constitutes 10+ key companies continuously working towards developing 12+ Aspergillosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Aspergillosis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Aspergillosis Market.
The Aspergillosis Pipeline report embraces in-depth…
More Releases for Pulmonary
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Embolism Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Pulmonary Embolism Market is exhibited at USD 1.59 billion in 2023 and is projected to surpass USD 3.15 billion in 2028, anticipated to grow at a CAGR of 8.4% from 2023 to 2028.
The rapid increase in the prevalence of cancer, increasing investment for healthcare infrastructure and rising research and development activities, high disposable income, rising demand…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
